Saturday 17 October 2026 Export NGNE’s income statement to Excel — free account

Neurogene Inc.

Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00. In the quarter to June 2026, EPS fell 45.7%, free cash flow fell 23.0% and total debt fell 66.7%, each against the same quarter a year earlier.

23.27 0.68 −2.84%

Follow NGNE

Alert me

Market cap: $479.3M
P/E: 0.0×
Fwd P/E: −4.5×
Dividend yield: —
F-score: n/a
Altman Z: 8.68
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.13

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	1	5	—	1	—	2	—	—	—

Insider Ownership 25.68%

Capital & Financial Ratios $m

Market Cap 479.27

Revenue —

Net Income (111.11)

Free Cash Flow (87.71)

Net Debt (225.39)

Current Ratio 10.64

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (4.45)

P/S ratio 0.00

P/B ratio 2.42

Past 5Y EPS Growth —

This Y EPS Growth (32.93%)

Next Y EPS Growth 7.29%

Next Y revenue growth (16.67%)

Next 5Y EPS Growth (2.85%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 62.71%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	197	312	269	225
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	3	4	3	4
	200	316	272	229

	2023	2024	2025	Q'26
Payables	3	1	2	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	23	15	16	22

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	9.34%	6.74%	39.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	1	—	—	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(24)	—	—	—
’25	(21)	(19)	(20)	(17)	(77)
’24	(22)	(16)	(16)	(17)	(71)
’23	(14)	(9)	(12)	(17)	(51)
’22	(14)	(11)	(9)	(18)	(53)
’21	(13)	(13)	(9)	(12)	(48)
’20	(6)	(9)	0	(9)	(25)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(24)	—	—	—
’25	(22)	(20)	(20)	(18)	(78)
’24	(22)	(16)	(16)	(18)	(71)
’23	(14)	(9)	(12)	(17)	(52)
’22	(15)	(12)	(10)	(19)	(55)
’21	(14)	(14)	(9)	(13)	(51)
’20	(7)	(10)	(1)	(10)	(27)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.39)	(1.53)	—	—	—
’25	(1.08)	(1.05)	(0.99)	(1.12)	(4.24)
’24	(1.00)	(1.09)	(1.19)	(0.99)	(4.28)
’23	(28.26)	(26.71)	(32.68)	79.85	(7.80)
’22	(5.60)	(5.60)	(4.80)	(4.80)	(139.72)
’21	(5.40)	(5.40)	(5.60)	(5.60)	(22.00)
’20	(3.60)	(4.00)	(0.80)	(4.80)	(12.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	120.28	200.40	39.20	42.80	116.20	92.00	7.50	9.38	14.44	6.88	Analyst estimates 2026–2028 Powerpack
	High	366.94	399.40	338.00	268.60	362.60	317.80	107.00	19.38	74.49	37.27
People
People	Employees	38	51	8	36	70	91	56	91	107	131
	Revenue/emp, $m	0.00	0.00	3.13	0.00	0.00	0.00	0.00	0.00	0.01	0.00
Income, $m
Income, $m	Revenue	—	—	25	—	—	—	—	—	1	—
	Gross margin, %	—	—	100.00	0.00	0.00	0.00	0.00	—	100.00	—
	EBT	(37)	(50)	(32)	(69)	(33)	(61)	(55)	(36)	(75)	(90)
	EBT margin, %	0.00	0.00	(126.34)	0.00	0.00	0.00	0.00	0.00	(8,123.68)	0.00
	Net income	(37)	(50)	(32)	(69)	(33)	(61)	(55)	(36)	(75)	(90)
	Depreciation	—	0	0	1	2	2	3	3	1	(1)
Per share, $
Per share, $	Revenue	0.00	0.00	21.26	0.00	0.00	0.00	0.00	0.00	0.05	0.00
	Earnings	(39.20)	(42.80)	(26.80)	(51.40)	(12.80)	(22.00)	(139.72)	(73.81)	(4.28)	(4.24)
	Cash flow	(32.00)	(38.14)	(26.85)	(11.39)	(9.48)	(17.28)	(133.73)	(104.52)	(4.02)	(3.62)
	Capex	(0.75)	(0.42)	(0.04)	(0.65)	(0.86)	(1.19)	(5.65)	(0.65)	(0.05)	(0.06)
	Free cash flow	(32.75)	(38.56)	(26.89)	(12.04)	(10.34)	(18.47)	(139.38)	(105.17)	(4.07)	(3.67)
	Book value	153.13	84.34	61.80	104.84	73.79	51.91	249.69	378.10	17.67	12.42
	Shares, m	1	1	1	1	3	3	0	0	18	21
Valuation, ×
Valuation, ×	P/E	—	—	0.00	—	—	—	—	—	0.00	—
	P/S	—	—	0.00	—	—	—	—	—	0.00	—
	P/B	—	—	0.70	—	—	—	—	—	1.29	—
	EV/Sales	—	—	0.00	—	—	—	—	—	0.00	—
	EV/FCF	—	—	0.83	—	—	—	—	—	(1.25)	—
Cash, $m
Cash, $m	Operating cash flow	(30)	(45)	(32)	(15)	(25)	(48)	(53)	(51)	(71)	(77)
	Capex	(1)	0	0	(1)	(2)	(3)	(2)	0	(1)	(1)
	Free cash flow	(31)	(45)	(32)	(16)	(27)	(51)	(55)	(52)	(71)	(78)
Balance, $m
Balance, $m	Working capital	94	98	73	139	187	135	78	177	301	255
	Total debt	0	0	0	0	0	0	0	0	0	0
	Net debt	(103)	(108)	(77)	(143)	(192)	(142)	(82)	(197)	(312)	(269)
	Shareholders’ equity	145	99	73	142	191	143	99	186	310	265
Returns, %
Returns, %	ROA	(27.64)	(37.92)	(33.61)	(61.82)	(18.61)	(32.47)	(40.50)	(21.89)	(26.92)	(28.94)
	ROIC	(56.49)	0.00	0.00	0.00	0.00	(8,175.92)	(211.87)	0.00	0.00	0.00
	ROE	(29.24)	(41.21)	(36.82)	(64.79)	(19.99)	(36.33)	3,839.23	(180.30)	(30.28)	(31.41)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MNPR Monopar Therapeutics Inc.	$481.9M	— (loss-making)	—	—	n/m	−201.41% (below 0%: shrinking)	—	0.00%	Compare
ENTX Entera Bio Ltd.	$481.5M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	−108.86% (below 0%: shrinking)	0.00%	0.00%	Compare
NGNE Neurogene Inc.	$479.3M	— (loss-making)	— (loss-making)	—	n/m	−22.97% (below 0%: shrinking)	100.00%	0.00%
YDES YD Bio Limited	$477.5M	—	—	—	—	—	—	—	Compare
RGNX REGENXBIO Inc.	$472.7M	— (loss-making)	— (loss-making)	+405.73% (above 0%: growing)	n/m	−26.67% (below 0%: shrinking)	99.04%	27.09%	Compare
ARVN Arvinas, Inc.	$468.2M	53.6×	— (loss-making)	+1,014.73% (above 0%: growing)	n/m	+49.79% (above 0%: growing)	96.40%	65.72%	Compare
CBIO Crescent Biopharma, Inc.	$463.6M	— (loss-making)	— (loss-making)	+1,038,900.00% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	100.00%	0.00%	Compare
ALLO Allogene Therapeutics, Inc.	$463.0M	— (loss-making)	— (loss-making)	+20,990.91% (above 0%: growing)	n/m	+17.73% (above 0%: growing)	100.00%	(1,011.21%)	Compare
ALT Altimmune, Inc.	$459.1M	— (loss-making)	— (loss-making)	+520.00% (above 0%: growing)	n/m	−25.27% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$470.4M	—	—	+767.37%	—	−25.27%	99.52%	0.00%

All 614 Biotechnology stocks →

Neurogene Inc. (NGNE) key facts

Neurogene Inc. (NGNE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00.
As of October 16, 2026, NGNE traded at $23.27, a market capitalization of $479.3 million.
Return on equity was −31.4% and debt-to-equity 0.00.
Its Altman Z-score is 8.68 (safe zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.